Search results
Results from the WOW.Com Content Network
25C-NBOMe (NBOMe-2C-C, 2C-C-NBOMe, Cimbi-82) is a psychedelic drug and derivative of the psychedelic phenethylamine 2C-C. 25C-NBOMe appeared on online vendor sites in 2010 but was not reported in the literature until 2011. [3]
The 25-NB (25x-NBx) series, or NBOMe series, also known as the N-benzylphenethylamines, is a family of serotonergic psychedelics. [1] [2] They are substituted phenethylamines and were derived from the 2C family. [2] The most commonly encountered NBOMe drugs are 25I-NBOMe, 25B-NBOMe, and 25C-NBOMe. [3]
In vitro studies, 25C-NBOMe has been shown to exhibit cytotoxicity on neuronal cell lines SH-SY5Y, PC12, and SN471, and the compound was more potent than methamphetamine at reducing the visibility of the respective cells; the neurotoxicity of the compound involves activation of MAPK/ERK cascade and inhibition of Akt/PKB signaling pathway.
In vitro studies, 25C-NBOMe has been shown to exhibit cytotoxicity on neuronal cell lines SH-SY5Y, PC12, and SN471, and the compound was more potent than methamphetamine at reducing the visibility of the respective cells; the neurotoxicity of the compound involves activation of MAPK/ERK cascade and inhibition of Akt/PKB signaling pathway.
25D-NBOMe (or NBOMe-2C-D) is a derivative of the phenethylamine derived hallucinogen 2C-D. It acts in a similar manner to related compounds such as 25I-NBOMe , which is a potent agonist at the 5-HT 2A receptor .
25B-NBOMe (NBOMe-2C-B, Cimbi-36, Nova, BOM 2-CB) is a derivative of the phenethylamine psychedelic 2C-B, discovered in 2004 by Ralf Heim at the Free University of Berlin. It acts as a potent full agonist for the 5HT 2A receptor .
25CN-NBOMe (2C-CN-NBOMe, NBOMe-2C-CN) is a derivative of the phenethylamine 2C-CN. It acts in a similar manner to related compounds such as 25I-NBOMe , which are potent agonists at the 5HT 2A receptor .
25CN-NBOH is notable as one of the most selective agonists of the serotonin 5-HT 2A receptor yet discovered, with an affinity (pK i) of 8.88 at the human serotonin 5-HT 2A receptor, 100-fold selectivity for the serotonin 5-HT 2A receptor over the serotonin 5-HT 2C receptor, and 46-fold selectivity for the serotonin 5-HT 2A receptor over the serotonin 5-HT 2B receptor.